Testing rituximab for heart attack patients
Part of Heart & circulation clinical trials.
This study tests whether adding the drug rituximab to standard heart attack treatment can reduce damage to the heart muscle after a heart attack. Rituximab is usually used for immune system conditions, and it may help calm inflammation and protect the heart. Participants must have a certain type of heart attack and be treated quickly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must be having a type of heart attack called ST-elevation myocardial infarction (STEMI) that affects the front or lower part of the heart with significant blockage.
- Your heart attack symptoms must have started within the last 48 hours.
- You must be scheduled to have a procedure to open the blocked artery (primary PCI) within 2 hours of diagnosis.
- You must be able to receive the study drug (rituximab) within 3 hours of that procedure.
- You must not have had a previous heart attack that left your heart pumping weakly (ejection fraction less than 50%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called RTP-026 for people having a serious heart attack (STEMI). It looks at whether the medicine is safe and helps the heart recover better when given along with the standard procedure to open the blocked artery.
This study tests a new drug called ziltivekimab to see if it helps people who have recently had a heart attack. The drug is given as an injection and compared to a placebo (a shot with no active medicine).
This trial tests whether a low-dose clot-busting medicine placed into the heart artery after a primary stent can improve outcomes in people with a certain type of heart attack. It also involves short hospital follow-ups and a heart MRI to look at how the heart is recovering.
This trial tests a new drug given shortly after a first heart attack to see if it can reduce heart damage when blood flow is restored. It is for patients having a specific type of heart attack (STEMI) and getting a procedure to open the blocked artery within 6 hours of symptoms starting.
This study tests a drug called ziltivekimab to see if it can reduce fatty plaque buildup in heart arteries after a heart attack. It's for people who had a heart attack treated with a stent and have mild blockages in other arteries.
This trial tests whether combining antioxidant supplements with standard heart attack care can reduce heart muscle damage. It may help people who are getting emergency treatment for their first heart attack.
Hear when a new ST Elevated Myocardial Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.